| Axis Top Picks basket gave impressive returns of 31% YoY & outperformed Nifty’s 8% return. Check new recommendations | |
| Company: | Model Portfolio |
| Brokerage: | Axis Securities |
| Date of report: | December 9, 2023 |
| Type of Report: | Model Portfolio |
| Recommendation: | Buy |
| Upside Potential: | 32% |
| Summary: | Based on the above themes, we recommend the following stocks: ICICI Bank, Maruti Suzuki India, State Bank of India, Lupin ltd, Federal Bank, Varun Beverages, TVS Motors, Bharti Airtel, PNC infra, ITC, Relaxo, CIE Automotive India, Bank of Baroda, Westlife Foodworld, CreditAccess Grameen, JTL Industries |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Axis Securities, Model Portfolio |
| Cochin Shipyard to witness significant YoY growth in revenues & profitability. Buy for target price of Rs 1340: ICICI Direct | |
| Company: | Cochin Shipyard |
| Brokerage: | ICICI-Direct |
| Date of report: | November 28, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 20% |
| Summary: | We expect CSL to witness significant YoY growth in revenues & profitability over FY24-25E, led by execution pick-up in both the segments and increasing share of margin accretive ship-repair segment |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Cochin Shipyard, ICICI-Direct |
| Kaynes Technology has execution superiority in a favourable ecosystem. Buy for target price of Rs 2850: HDFC Sec | |
| Company: | Kaynes Technology |
| Brokerage: | HDFC Sec |
| Date of report: | November 28, 2023 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 16% |
| Summary: | Kaynes Technology (Kaynes) is one of the prominent players in electronics system design and manufacturing (ESDM) services with three decades of experience (mainly in B-B). |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | HDFC Sec, Kaynes Technology |
| Amara Raj is in value zone with attractive risk reward. Buy for target price of Rs 900 (27% upside) | |
| Company: | Amara Raja |
| Brokerage: | ICICI-Direct |
| Date of report: | December 1, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 27% |
| Summary: | With steady growth prospects in base business, increasing focus in new energy domain, merger of related businesses at fair value, healthy net cash positive B/S & inexpensive valuations, we have a positive view on the stock |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Amara Raja, ICICI-Direct |
| Pitti Engineering: Strategic operation will support improving ROE and ROCE to 25.8% and 26.7%. Buy for target price of Rs 915 (40% upside) | |
| Company: | Pitti Engineering |
| Brokerage: | Axis Securities |
| Date of report: | December 1, 2023 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 40% |
| Summary: | We initiate coverage on Pitti Engineering Ltd. (PEL) with a BUY recommendation. Our recommendation is supported by a) The company’s increasing capacity b) Its increasing share of value-added products, and c) Its expanding global footprints |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Axis Securities, Pitti Engineering |
| Review of 9 Specialty Chemical Stocks And 3 Stock Recommendations by Axis Securities | |
| Company: | Speciality Chemicals stocks |
| Brokerage: | Axis Securities |
| Date of report: | November 26, 2023 |
| Type of Report: | Sector Report |
| Recommendation: | Buy |
| Upside Potential: | 100% |
| Summary: | Structural story of Indian Chemical industry remains strong with strategic portfolio composition to gain export market share, and strong domestic demand we expect revenue growth to gain momentum from FY25 onward. Given the changing landscape and growing reliance on India by international customers, we expect rapid growth in this sector over the coming period as conditions stabilize |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Axis Securities, Speciality Chemicals |
| Pharma is back on Growth Track. Axis Securities recommends 3 top picks in the Pharma universe | |
| Company: | Aurobindo Pharma |
| Brokerage: | Axis Securities |
| Date of report: | November 25, 2023 |
| Type of Report: | Sector Report |
| Recommendation: | Buy |
| Upside Potential: | 100% |
| Summary: | Q2FY24 Pharma Review – Higher Profitability with Easing Price Erosion, New Launches, and Lower RM Prices |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Model Portfolio |
| LIC: Upgrade to BUY – Undemanding valuation; structural issues priced-in: Emkay | |
| Company: | LIC |
| Brokerage: | Emkay |
| Date of report: | November 12, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 25% |
| Summary: | We upgrade the stock to BUY, as we believe higher surplus generation and slower growth could lead to a step jump in dividend, as solvency is healthy. |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Emkay, LIC |
| PSP Projects has a sturdy foundation & promising future prospects. Buy for target price of Rs 905: SMIFS | |
| Company: | PSP Projects Ltd |
| Brokerage: | SMIFS |
| Date of report: | November 24, 2023 |
| Type of Report: | Initiating Coverage |
| Recommendation: | Buy |
| Upside Potential: | 20% |
| Summary: | Additionally, well-managed balance sheet, strict working capital controls, and healthy return ratios are added positives. Given the favourable outlook, we initiate coverage with a Target Price of Rs905/share (15x Sept’25 estimated EPS), representing an upside potential of ~20% |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | PSP Projects Ltd, SMIFS |
| Royal Orchid Hotels will outpace peers & narrow valuation gap with its peers. Buy for target price of Rs 498 (76% upside): Nuvama | |
| Company: | Royal Orchid Hotels |
| Brokerage: | Nuvama |
| Date of report: | November 14, 2023 |
| Type of Report: | Result Update |
| Recommendation: | Buy |
| Upside Potential: | 76% |
| Summary: | Strong room addition pipeline one of the key growth drivers. Expect revenue/EBITDA to clock 29%/18% CAGR over FY23–25 |
| Full Report: | Click here to view full post with link to download pdf file |
| Tags: | Nuvama, Royal Orchid Hotels |